

SECURITIES AND EXCHANGE COMMISSION

FORM CT ORDER

Confidential treatment order

Filing Date: **2013-01-28**
SEC Accession No. [999999997-13-000464](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

STEMLINE THERAPEUTICS INC

CIK: [1264587](#) | IRS No.: [450522567](#) | State of Incorporation: **DE** | Fiscal Year End: **1231**
Type: **CT ORDER** | Act: **33** | File No.: [333-180515](#) | Film No.: [13552082](#)
SIC: **2834** Pharmaceutical preparations

Mailing Address
*750 LEXINGTON AVENUE
NEW YORK NY 10022*

Business Address
*750 LEXINGTON AVENUE
NEW YORK NY 10022
212-831-1111*

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
January 28, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Stemline Therapeutics, Inc.

File No. 333-180515 - CF#28193

Stemline Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 filed on April 02, 2012.

Based on representations by Stemline Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1	through June 19, 2015
Exhibit 10.2	through June 19, 2015
Exhibit 10.3	through June 19, 2015
Exhibit 10.4	through June 19, 2015
Exhibit 10.5	through June 19, 2015

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Dan Greenspan
Legal Branch Chief